SCHEMBL17619213

SCHEMBL17619213

C=CCOC(=O)NCCc1cc(=O)oc2cc(O)ccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.68
HSD17B3 P37058 9/20 0.53
ALDH1A1 P00352 2/20 0.52
GAA P10253 2/20 0.52
KDM4E B2RXH2 2/20 0.52
GLA P06280 2/20 0.52
ERAP1 Q9NZ08 1/20 0.51
LCK P06239 1/20 0.50
FYN P06241 1/20 0.50
AKR1B1 P15121 1/20 0.50
GRB2 P62993 1/20 0.50
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17619212 0.85 ERN1 (0.59) ERN1ALDH1A1GAAKDM4EGLA
SCHEMBL26876905 0.83 ERN1 (0.61) ERN1ALDH1A1GAAKDM4EGLA
SCHEMBL29209118 0.81 ERN1 (0.57) ERN1ALDH1A1GAAKDM4ELCK
SCHEMBL30672589 0.81 ERN1 (0.59) ERN1ALDH1A1GAAKDM4EGLA
SCHEMBL30848799 0.81 ERN1 (1.00) ERN1ALDH1A1GAAKDM4EGLA
SCHEMBL16208775 0.81 ERN1 (1.00) ERN1ALDH1A1GAAKDM4EGLA
SCHEMBL16197641 0.80 HSD17B3 (0.64) HSD17B3ALDH1A1GAAKDM4EGLA
SCHEMBL30848898 0.78 ERN1 (0.47) ERN1HSD17B3ALDH1A1GAAKDM4E
SCHEMBL30848862 0.76 ERN1 (0.46) ERN1HSD17B3ALDH1A1GAAKDM4E
SCHEMBL739294 0.74 HSD17B3 (0.68) HSD17B3ALDH1A1GAAKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294487-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2024-09-05 US disclosed
US-11945789-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2024-04-02 US disclosed
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF XBP1, RRP1B, ERN1 ERN1 3/4885HSD17B3 3450/4885ALDH1A1 2009/4885
US-11945789-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof XBP1, DDIT3, ERN1 ERN1 3/4885HSD17B3 2599/4885ALDH1A1 2871/4885
US-20240294487-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF XBP1, DDIT3, ERN1 ERN1 3/4885HSD17B3 2599/4885ALDH1A1 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.